Blog

2024 Hamburg Awardees for Advances in Biomedical Research and Clinical Medicine – Dana-Farber Cancer Institute

Collage photo of Gordon Freeman and Arlene Sharpe

Oct 31, 2024, 08:36

2024 Hamburg Awardees for Advances in Biomedical Research and Clinical Medicine – Dana-Farber Cancer Institute

Recently, Gordon Freeman and Arlene Sharpe Received the Hamburg Award from the National Academy of Medicine for Discoveries Leading to New, Effective Immunotherapies

Gordon J. Freeman, Ph.D., is a Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, recognized for discovering the immune checkpoint proteins PD-L1 and PD-L2. He earned his Ph.D. in Microbiology and Molecular Genetics from Harvard University.

He is a member of the National Academy of Sciences and the National Academy of Inventors, a Fellow of the AACR and SITC Academies, and a recipient of the William B. Coley Award, the Warren Alpert Foundation Prize, and the Richard Smalley, MD, Memorial Award.

Arlene Sharpe, MD, PhD, is the Kolokotrones University Professor at Harvard University and Chair of the Department of Immunology at Harvard Medical School. She serves in the Department of Pathology at Brigham and Women’s Hospital, the Broad Institute of MIT and Harvard, and leads the Cancer Immunology Program at Dana-Farber/Harvard Cancer Center.

Additionally, she is Vice Director of the Gene Lay Institute of Immunology and Inflammation. Renowned for her work in T cell costimulation, Dr. Sharpe’s research defined key roles of the CTLA-4 and PD-1 pathways in immune inhibition, laying the groundwork for immune checkpoint blockade therapies in cancer.

On this occasion, Dana-Farber Cancer Institute shared a post on LinkedIn:

“Congratulations to Dana-Farber’s Gordon Freeman, PhD, and Harvard Medical School’s Arlene Sharpe, PhD, recipients of the 2024 Hamburg Award for Advances in Biomedical Research and Clinical Medicine in recognition of their groundbreaking research that enabled the development of immunotherapies for cancer.”

Read further.

More posts featuring Dana-Farber Cancer Institute.

Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a leading institution for cancer treatment and research. It was founded by Sidney Farber on 1947.

Currently, the Institute has over 5,000 staff, faculty, and clinicians on board. They manage in excess of 640,000 outpatient visits each year, oversee more than 1,000 hospital discharges annually, and are actively involved in over 1,100 ongoing clinical trials.

As of 2023, Dana-Farber is ranked as the #4 cancer hospital globally. Dana-Farber’s research contributions include the development of Gleevec, a highly successful treatment for chronic myeloid leukemia.